Arc-1 review

Arc-1 combines a longevity storefront with prescription assessment. Rapamycin is the distinguishing offer: its page advertises $114.99 per month with a subscription and a higher one-time price for 12 capsules. It also advertises no consultation fee and free shipping. Those are the provider’s public offer terms, rather than a promise that every future refill stays unchanged. The general terms allow prices to change and identify Arc-1 Metrics, PLLC as the contracting business. Before subscribing, obtain the exact refill quantity, capsule strength, renewal date and duration represented by each charge. The page describes a cycling regimen, but that does not establish a capsule’s labeled strength or an appropriate schedule for you. The rapamycin evidence guide explains why longevity use remains distinct from approved medical indications.

The product page does not clearly establish whether the dispensed rapamycin is an approved generic sirolimus product or a compounded preparation. That distinction matters more than the shared molecule name. Ask for the manufacturer or compounding pharmacy, formulation and prescription label before accepting the order. Arc-1’s marketing discusses possible healthy-aging benefits; those statements do not demonstrate that its particular product extends human lifespan. Nor does a founder’s clinical background validate every use promoted in a storefront. A clinician should assess the treatment, interactions, monitoring and alternatives for the individual patient. The published price alone does not establish which laboratory tests are included, who orders them or how an abnormal result is handled. The rapamycin access guide separates a prescribing route from evidence of a longevity benefit.

The GLP-1 product pages direct customers to complete checkout before the secure medical intake, followed by practitioner review and approval before shipment. The general workflow page describes intake and review but does not specify payment capture. The product-specific sequence does not establish that a submitted payment is only an authorization hold. Ask what is collected before clinical review and what is returned if no prescription is issued. Arc-1 advertises compounded semaglutide from $199.99 and tirzepatide from $199.99 at their entry options. Current public variant data show higher prices for higher listed doses. The tirzepatide page’s lower promotional headline disagrees with its entry variant and homepage, so confirm the complete checkout amount rather than treating the banner as a binding quote. The tirzepatide cost guide explains how to compare a starting offer with the price of ongoing care.

The tirzepatide page identifies a combination containing glycine and B12. It also uses language suggesting effectiveness comparable with branded options, while the semaglutide page mixes FDA-approved-drug language with a compounded-product offer and still refers to a shortage-based supply rationale. Those claims should not be read as FDA approval, clinical equivalence or proof of a currently applicable compounding exemption. A compounded product is not an FDA-approved version of Wegovy or Zepbound, and brand trials do not establish the quality or outcomes of this specific preparation. Ask the clinician and pharmacy why a compounded product is medically appropriate and how it meets applicable requirements. The pharmacy-check guide explains the difference between a published partner claim and a verified dispensing location.

Arc-1 names founder Todd Stearns and describes him as a board-certified physician; the homepage offers a 20-minute founder consultation. This is an attributed provider biography, not an independent check of current credentials or proof that he handles every prescription. The reviewed pages refer to licensed practitioners and US-licensed compounding pharmacies without identifying the exact clinician and dispensing location assigned to a customer. FDA registration and a pharmacy’s license are different concepts, and neither should be inferred solely from a site badge. The support page directs medication questions through an order’s Chat with Doctor button and advertises a one-business-day response. That is a service expectation rather than a guaranteed emergency response. Product pages also publish different state exclusions: tirzepatide excludes California, Arkansas, Indiana, Minnesota and South Carolina; the rapamycin and semaglutide pages additionally name Puerto Rico but do not list California. Confirm the exact product and destination before paying. The return documents require care. The general refund policy describes a 30-day request window for unused items in original packaging, prior return authorization and product exceptions. It says an approved refund may take six to eight weeks. The support page is more specific: prescriptions generally cannot be returned, with damaged or lost products directed to support. That does not establish a no-risk medication trial or a guaranteed refund after clinical denial. The public pages reviewed do not settle a subscription-specific cancellation deadline or the disposition of a payment when no prescription is approved. Ask for those answers before accepting a recurring order, and retain the written response. Account tools allow delivery-schedule and payment changes, but managing a subscription is different from reversing a charge or returning dispensed medication. The program billing checklist can keep those unresolved conditions alongside a competing written offer.